The advanced therapy sector is transitioning from niche applications to broader mainstream use, focusing on three key areas: research and development (R&D), manufacturing, and commercial strategy. In R&D, treatments are expanding beyond oncology to include common conditions like osteoarthritis and type 1 diabetes, with improvements in safety profiles for therapies like CAR-T. Manufacturing advancements highlight a shift toward automated, reliable systems that can enhance scalability, though challenges in quality control and supply chain management persist. Commercially, there’s a pressing need to adapt models for better access and affordability of therapies, involving early payer engagement and expanded community delivery networks. The evolving landscape underscores the importance of collaboration between biotech companies and academic centers to democratize access to advanced therapies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.deloitte.com/us/en/insights/industry/health-care/cell-and-gene-therapies-growth-innovation.html
